Eric T. Kimchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eric T. Kimchi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kevin F. Staveley-O'Carroll
Department of Surgery, Pennsylvania State University College of Medicine, 500 University Drive, H070, Hershey, PA 17033, USA
2 shared publications - Niraj Jaysukh Gusani
Baptist MD Anderson Canc Ctr, Sect Surg Oncol, Jacksonville, FL 32207 USA
2 shared publications - David T Dicker
Laboratory of Translational Oncology and Experimental Cancer Therapeutics; Division of Hematology/Oncology; Department of Medicine; Penn State Hershey Cancer Institute; Pennsylvania State University; Hershey, PA USA
1 shared publication Diego Avella
1 shared publication- Guangfu Li
Department of Surgery, University of Missouri, Columbia, Missouri, USA
1 shared publication - Junjia Zhu
Penn State College of Medicine, Department of Public Health Sciences, Pennsylvania State University, MC CH69, 500 University Drive, P.O. Box 850, Hershey, PA, 17033, USA
1 shared publication
Latest Publications
- Open Access
- 1 December 2013
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 14 (12) , 1174-1181
Circulating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients
Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when combining both genders. Circulating tumor cells (CTCs) are a prognostic marker for stage IV CRC patients. We hypothesized that CTC quantity varies among stage IV CRC populations. Methods Blood (7.5 ml) was prospectively collected from 90 stage IV CRC patients. EpCAM+ CTCs were analyzed with the FDA-approved CellSearch® system. CRC tumors were immunohistochemically stained for EpCAM expression. Imaging and clinicopathological data were collected. Statistical analysis was performed using correlation analysis, Kruskal–Wallis, Fisher exact, and log-rank test. Results CTCs were detectable in 36/90 (40%) patients. Diffuse CRC metastases were associated with the highest CTC prevalence (24/40 [60%]), in contrast to limited lung (2/19 [11%]) or liver (10/31 [32%]) metastases (P = 0.027). The overall mean CTC number was 2.0 (range 0–56.3). The mean CTC number in patients with diffuse metastases was significantly higher (3.7 [SEM ± 1.7, range 0–56.3]) than with limited lung metastases (0.1 [± 0.1; range 0–1]) or liver metastases (0.9 [± 0.3, range 0–7.0]) (P = 0.001). CRC tumors were consistently expressing EpCAM. CTC numbers did not correlate with serum CEA levels or other routine clinical parameters (P = N.S.). Patients with diffuse metastases had the poorest overall survival (P = 0.0042). Conclusions CRC patients with diffuse metastases have the highest number of CTCs, in contrast to limited metastases to the liver or lungs. Future studies should correlate CTCs with recurrence patterns in patients with resected CRC lung or liver metastases to investigate whether CTCs represent micrometastatic disease causing early relapses.
- 1 December 2013
- Published by Taylor & Francis in Cancer Biology & Therapy
- Vol. 14 (12) , 1174-1181
Open AccessCirculating tumor cells are associated with diffuse spread in stage IV colorectal cancer patients
Background Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when combining both genders. Circulating tumor cells (CTCs) are a prognostic marker for stage IV CRC patients. We hypothesized that CTC quantity varies among stage IV CRC populations. Methods Blood (7.5 ml) was prospectively collected from 90 stage IV CRC patients. EpCAM+ CTCs were analyzed with the FDA-approved CellSearch® system. CRC tumors were immunohistochemically stained for EpCAM expression. Imaging and clinicopathological data were collected. Statistical analysis was performed using correlation analysis, Kruskal–Wallis, Fisher exact, and log-rank test. Results CTCs were detectable in 36/90 (40%) patients. Diffuse CRC metastases were associated with the highest CTC prevalence (24/40 [60%]), in contrast to limited lung (2/19 [11%]) or liver (10/31 [32%]) metastases (P = 0.027). The overall mean CTC number was 2.0 (range 0–56.3). The mean CTC number in patients with diffuse metastases was significantly higher (3.7 [SEM ± 1.7, range 0–56.3]) than with limited lung metastases (0.1 [± 0.1; range 0–1]) or liver metastases (0.9 [± 0.3, range 0–7.0]) (P = 0.001). CRC tumors were consistently expressing EpCAM. CTC numbers did not correlate with serum CEA levels or other routine clinical parameters (P = N.S.). Patients with diffuse metastases had the poorest overall survival (P = 0.0042). Conclusions CRC patients with diffuse metastases have the highest number of CTCs, in contrast to limited metastases to the liver or lungs. Future studies should correlate CTCs with recurrence patterns in patients with resected CRC lung or liver metastases to investigate whether CTCs represent micrometastatic disease causing early relapses.
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 347
QS202. Alloderm Mesh An Innovative Tool for Diaphragmatic Reconstruction in Patients With Large Retroperitoneal Sarcomas
- 29 February 2008
- Published by Elsevier in Journal of Surgical Research
- Vol. 144 (2) , 347
QS202. Alloderm Mesh An Innovative Tool for Diaphragmatic Reconstruction in Patients With Large Retroperitoneal Sarcomas